Apple hires secret team for treating diabetes: CNBC
FILE PHOTO: An Apple logo is seen in a store in Los Angeles, California, U.S., March 24, 2017. REUTERS/Lucy Nicholson/File Photo
(Reuters) - Apple Inc has hired a team of biomedical engineers as part of a secret initiative, initially envisioned by late Apple co-founder Steve Jobs, to develop sensors to treat diabetes, CNBC reported citing three people familiar with the matter.
An Apple spokeswoman declined to comment.
The engineers are expected to work at a nondescript office in Palo Alto, California, close to the corporate headquarters, CNBC said. (http://cnb.cx/2nGgn9P)
The news comes at the time when the line between pharmaceuticals and technology is blurring as companies are joining forces to tackle chronic diseases using high-tech devices that combine biology, software and hardware, thereby jump-starting a novel field of medicine called bioelectronics.
Last year, GlaxoSmithKline Plc and Google parent Alphabet Inc unveiled a joint company aimed at marketing bioelectronic devices to fight illness by attaching to individual nerves.
U.S. biotech firms Setpoint Medical and EnteroMedics Inc have already shown early benefits of bioelectronics in treating rheumatoid arthritis and suppressing appetite in the obese.
Other companies playing around the idea of bioelectronics include Medtronic Plc , Proteus Digital Technology, Sanofi SA and Biogen Inc .
The company's shares were marginally up after the bell on Wednesday.
(Reporting by Divya Grover in Bengaluru; Editing by Sandra Maler and Lisa Shumaker)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Apple alleges defendant in trade secret case against OpenAI accessed power converter circuit schematic while at OpenAI - legal filing
- VivoSim Labs plans rat liver model to pair with human platform
- Butterfly Network and Merge Labs sign BCI ultrasound licensing deal
Create E-mail Alert Related Categories
Corporate News, ReutersRelated Entities
Steve JobsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share